Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
81-100 of 991 trials

Small Cell Lung Cancer: Trilaciclib vs Placebo

We are studying whether trilaciclib can improve survival for patients with extensive stage small cell lung cancer receiving chemotherapy. The trial will also assess its effects on tumor response and safety compared to a placebo.

Extensive Stage Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Pancreatic Cancer: New Treatment Combination Study

We are studying a new treatment combining autogene cevumeran, atezolizumab, and mFOLFIRINOX for patients with resected pancreatic ductal adenocarcinoma. The goal is to see if this combination improves survival compared to standard mFOLFIRINOX alone.

Pancreatic Cancer>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessCost ReimbursementOncology

Eplontersen for Transthyretin-Mediated Amyloid Cardiomyopathy

We are studying the long-term safety of eplontersen in adults with ATTR-CM. This trial will help us understand how well the treatment is tolerated over an extended period.

Transthyretin-Mediated Amyloid Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Prostate Cancer: ADT with Darolutamide

We are studying whether adding darolutamide to standard hormone therapy helps frail men with newly diagnosed metastatic prostate cancer live longer and feel better. This trial compares the new treatment to a placebo to assess its effectiveness.

Metastatic Prostate Cancer1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementOncology

Cardiovascular Safety: BI 456906 for Overweight Individuals

We are testing a new medication for people with overweight or obesity and cardiovascular disease to see if it is as safe as a placebo. The study will also look at its effects on blood pressure and waist size.

Obesity>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Advanced Cutaneous Squamous Cell Carcinoma: INCB099280 Study

We are evaluating a new medication for people with advanced cutaneous squamous cell carcinoma to see how safe it is and if it may help improve their condition.

Recurrent and Metastatic Skin Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Beta-Thalassemia: Luspatercept for Children

We are studying a new treatment called luspatercept for children with beta-thalassemia to find a safe dose and evaluate its effects on blood health. This trial includes both transfusion-dependent and non-transfusion-dependent participants.

Beta Thalassemia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Deucravacitinib for Pediatric Plaque Psoriasis

We are studying a new medication for children and teens with moderate to severe plaque psoriasis. The trial will help us understand how well it works and its safety compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyPediatrics

Eptinezumab for Pediatric Migraine Prevention

We are studying whether eptinezumab can help reduce the number of migraine days in children and teenagers with episodic migraines. This trial aims to find out if it is a safe and effective option for young patients.

MigraineConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Late-onset Pompe Disease: Cipaglucosidase Alfa and Miglustat Study

We are evaluating the safety and effectiveness of a new treatment for children with late-onset Pompe disease. This study aims to understand how well the medications work together and their effects on young patients.

Late-onset Pompe Disease1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyHematologyPediatrics

Lymphoma Treatment Study: Zanubrutinib vs. Lenalidomide

We are comparing the effectiveness of zanubrutinib combined with anti-CD20 antibodies against lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma. This study aims to find out which treatment works better and is safer.

Marginal Zone LymphomaFollicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Multiple Sclerosis: BIIB091 Treatment Study

We are studying the safety of BIIB091 alone and with Diroximel Fumarate in adults with relapsing forms of multiple sclerosis. The goal is to see how these treatments affect brain inflammation.

Relapsing Multiple Sclerosis1-2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesCost ReimbursementNeurology

Asthma Treatment: Povorcitinib Study

We are evaluating a new medication for adults with moderate to severe asthma that isn't well controlled. The study aims to see if it improves lung function and reduces asthma attacks.

Asthma3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Nipocalimab for Pregnancies at Risk of Severe Hemolytic Disease

We are studying whether Nipocalimab can help reduce the risk of fetal anemia in pregnant individuals at risk for severe hemolytic disease of the fetus and newborn. This trial compares the treatment to a placebo to assess its effectiveness.

Hemolytic Disease of the Fetus and Newborn>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsInfectious Diseases

Advanced Solid Tumors: TNG462 Treatment Study

We are testing a new treatment called TNG462 for patients with advanced solid tumors that have a specific genetic deletion. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Advanced or Metastatic Solid Tumors with MTAP Deletion>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Solid Tumors: SKB264 with Pembrolizumab

We are investigating whether the combination of SKB264 and pembrolizumab is safe and effective for people with selected solid tumors. This study will also explore how the body handles the new drug and its effects on the immune system.

Ovarian CancerCervical CancerUrothelial Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology

Non-Hodgkin Lymphoma: GLPG5101 Treatment Study

We are evaluating a new treatment called GLPG5101 for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aims to understand its safety and effectiveness compared to existing options.

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Relapsing Multiple Sclerosis: Rituximab vs. Ocrelizumab

We are studying whether rituximab is as effective as ocrelizumab for treating relapsing MS. This trial is for patients who are starting anti-CD20 therapy.

Multiple Sclerosis>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

IMC-F106C for Advanced PRAME-Positive Cancers

We are studying a new treatment called IMC-F106C for individuals with advanced PRAME-positive cancers. The trial aims to assess its safety and effectiveness, both alone and with other cancer therapies.

Urothelial CarcinomaNon-Small Cell Lung CancerOvarian Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Mifepristone as a Weekly Contraceptive

We are studying the effectiveness and safety of a weekly dose of mifepristone for contraception. This trial also looks at how well patients accept this method and any potential effects on liver function.

Oral Contraception1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and Obstetrics